+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy



Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy



British Journal of Radiology 84 Spec No 1: S54-S60



The aim of this study was to evaluate the influence of prognostic factors related to patient selection on survival outcomes. Survival outcomes were retrospectively analysed in a consecutive series of 67 newly diagnosed glioblastoma multiforme (GBM) patients who had received either conventional fractionated photon radiotherapy (CRT) or high-dose particle radiotherapy (HDT). In the CRT protocol, a total dose of 60.0-61.2 Gy was administered. In the HDT protocol, an average dose of approximately 30 GyE in a single session and additional fractionated photon irradiation of total dose 30 Gy were administered to patients receiving boron neutron capture therapy; and a total dose of 96.6 GyE was administered to patients receiving proton therapy. Most of the patients had received chemotherapy with nimustine hydrochloride (ACNU) alone or with ACNU, procarbazine and vincristine. The median overall survival (OS) and progression-free survival times for all patients were 17.7 months [95% confidence interval (CI), 14.6-20.9 months] and 7.8 months (95% CI, 5.7-9.9 months), respectively. The 1- and 2-year survival rates were 67.2% and 33.7%, respectively. For patients treated with HDT, the median OS was 24.4 months (95% CI, 18.2-30.5 months), compared with 14.2 months (95% CI, 10.0-18.3 months) for those treated with CRT. The Cox proportional hazards model revealed radiation modality (HDT vs CRT) and European Organisation for Research and Treatment of Cancer recursive partitioning analysis class to be the significant prognostic factors. Age, sex, pre-operative performance status, treatment with or without advanced neuroimaging, extent of surgery and regimen of chemotherapy were not statistically significant factors in predicting prognosis. The median OS was 18.5 months (95% CI, 9.9-27.1 months) in patients of 65 years and older, compared with 16.8 months (95% CI, 13.6-20.1 months) in those 64 years and younger (p=0.871). The positive effect of HDT treatment is unlikely to reflect patient selection alone. Randomised trials with strictly controlled inclusion criteria to ensure the comparable selection of patients are required to demonstrate conclusively that prolonged survival can be attributed to high-dose particle radiotherapies.

(PDF emailed within 0-6 h: $19.90)

Accession: 055210130

Download citation: RISBibTeXText

PMID: 21427185

DOI: 10.1259/bjr/29022270


Related references

Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol: in regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860). International Journal of Radiation Oncology, Biology, Physics 62(1): 296-7; Author Reply 297, 2005

Difference in pattern of failure between moderate dose conventional and high dose conformal techniques for postoperative radiotherapy of glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 39(2 SUPPL ): 276, 1997

The treatment of newly diagnosed glioblastoma multiforme using high dose tamoxifen , radiotherapy and conventional chemotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 431, 1997

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology, Biology, Physics 60(3): 853-860, 2004

Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors. Journal of Neuro-Oncology 9(1): 41-45, 1990

Postoperative chemo-radiotherapy with temodal in patients with glioblastoma multiforme--survival rates and prognostic factors. Folia Medica 52(1): 26-33, 2010

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiology and Oncology 45(3): 213-219, 2012

High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques 27(4): 302-306, 2000

Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncology 43(6): 535-543, 2006

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. Journal of Neurosurgery 90(1): 72-77, 1999

High-dose conformal radiotherapy for glioblastoma multiforme. Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 57(6): 330-335, 1997

Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. Journal of Neuro-Oncology 139(2): 411-419, 2018

Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme. Annals of Internal Medicine 144(5): I31-I31, 2006

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. Bmc Cancer 18(1): 105-105, 2018

High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. International Journal Of Radiation Oncology Biology Physics. 40(5): 1141-1149, Ch 15, 1998